07:06:45 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-28 Ordinarie utdelning CESSA 0.00 DKK
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2021-12-22 13:07:59

During the period 25 November - 16 December 2021, holders of TO 1 have been entitled to subscribe for shares with warrants. A total of 2,432,535 warrants were exercised, corresponding to 2,432,535 shares and an overall exercise rate of approximately 97 percent. In connection with the warrant exercise, Cessatech entered guarantee commitments (top-down) up to a maximum of DKK 2.5 million with a limited number of investors. Based on the successful outcome of the warrant exercise, the Board of Directors has decided to not activate the guarantee commitments. Thus, Cessatech will receive approximately DKK 24.3 million before deduction of transaction related costs of approximately DKK 1.7 million (corresponding to 6.82 percent of the issue volume in the Company's exercise of warrants).

Number of shares and share capital
When the new shares from the warrant exercise have been registered with Erhvervsstyrelsen, the Danish Companies Registration Office, the total number of shares will amount to 6,112,535 and the share capital will amount to DKK 1,222,507. The planned conversion date from interim to common shares is expected to take place on 13 January 2022. The common shares are expected to be visible in each subscriber's account around 17 January 2022.

"We are very happy with the successful warrant exercise and welcome all new and existing shareholders supporting us on our continued journey. We look forward to exciting 2022 and the many planned milestones ahead of us", Jes Trygved, CEO Cessatech A/S.

For further information regarding the exercise of warrants, please contact:
Sedermera Fondkommission
Phone: +46 40 - 615 14 10
E-mail: info@sedermera.se
www.sedermera.se

Nordic Issuing
Phone: +46 (0)40-632 00 20
E-mail: info@nordic-issuing.se
www.nordic-issuing.se

This disclosure contains information that Cessatech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-12-2021 13:08 CET.